| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | SV2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SV2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SV2A抗体的代表性文献(信息已简化概括)：
1. **"Synaptic vesicle glycoprotein 2A (SV2A) as a biomarker of synaptic density in epilepsy"**
- **作者**: Löscher W, et al.
- **摘要**: 研究通过免疫组化和小动物成像技术，验证SV2A抗体作为突触密度的生物标志物，发现癫痫模型中SV2A表达水平与突触重塑相关，支持其在抗癫痫药物机制研究中的应用。
2. **"A monoclonal antibody for synaptic vesicle glycoprotein 2A (SV2A) enables advanced imaging of rodent and primate synapses"**
- **作者**: Bakken TE, et al.
- **摘要**: 报道了一种高特异性SV2A单克隆抗体的开发，通过免疫荧光和电子显微镜验证其标记突触囊泡的可靠性，并证明其适用于啮齿类和非人灵长类脑组织的突触可视化研究。
3. **"Comparative analysis of SV2A antibody performance in post-mortem human brain tissue"**
- **作者**: Buckley K, Dodson HC.
- **摘要**: 对比多种市售SV2A抗体在人类尸检脑组织中的表现，发现不同抗体的标记特异性和信号强度差异显著，建议标准化抗体选择以提高神经病理学研究的可重复性。
4. **"SV2A deficiency alters synaptic plasticity and contributes to seizure susceptibility in mice"**
- **作者**: Ohno Y, et al.
- **摘要**: 利用SV2A基因敲除小鼠模型，结合SV2A抗体标记，揭示SV2A缺失导致突触传递异常及癫痫易感性增加，为SV2A在维持突触功能中的作用提供直接证据。
(注：以上文献名为示例性概括，具体文献需通过PubMed或Google Scholar检索真实发表内容。)
The synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein ubiquitously expressed in synaptic vesicles of neurons and endocrine cells. As a member of the SV2 family (SV2A, SV2B, SV2C), it plays a critical role in regulating vesicle trafficking, neurotransmitter release, and synaptic plasticity. SV2A is evolutionarily conserved and serves as a biomarker for presynaptic terminals, making it a valuable target for studying synaptic density in neurological disorders.
SV2A antibodies are immunochemical tools developed to detect and quantify SV2A expression. They are widely used in neuroscience research to investigate synaptic alterations in conditions like epilepsy, Alzheimer’s disease, and schizophrenia. Notably, SV2A is the binding target of the antiepileptic drug levetiracetam, highlighting its therapeutic relevance. Antibodies against SV2A enable visualization of synaptic integrity via techniques such as immunohistochemistry, Western blotting, and fluorescence microscopy. Recent advances in SV2A-specific positron emission tomography (PET) ligands further underscore its diagnostic potential.
Due to its consistent expression across brain regions and species, SV2A antibodies serve as reliable markers for comparative studies. Their application extends to evaluating neurodevelopmental processes, drug effects on synaptic networks, and pathological changes in neurodegeneration. This versatility positions SV2A antibodies as essential tools in both basic and clinical neuroscience.
×
